

GIVING LIFE TO SCIENCE™



## PureTech to Present at Three Upcoming Investor Conferences

November 16, 2020

RNS Number : 3438F  
PureTech Health PLC  
16 November 2020

16 November 2020

PureTech Health plc

PureTech to Present at Three Upcoming Investor Conferences

[PureTech Health](#) plc (LSE: PRTC, Nasdaq: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced that members of the Management Team will present at the following upcoming virtual investor conferences. Webcasts of the presentations will be available at <https://investors.puretechhealth.com>.

### Jefferies 2020 Virtual London Healthcare Conference

Presenter: Daphne Zohar, founder and chief executive officer  
Date: Wednesday, November 18, 2020  
Time: 9:05 AM EST

### Piper Sandler 32<sup>nd</sup> Annual Virtual Healthcare Conference

Presenters: Daphne Zohar, founder and chief executive officer; Eric Elenko, chief innovation officer  
Date: Fireside Chat available as of 10:00 AM EST on Monday, November 23, 2020

### Evercore ISI 3<sup>rd</sup> Annual HealthCONx Conference

Presenters: Daphne Zohar, founder and chief executive officer; Eric Elenko, chief innovation officer  
Date: Wednesday, December 2, 2020  
Time: 4:20 PM EST

### About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, including intractable cancers, lymphatic and gastrointestinal diseases, central nervous system disorders and inflammatory and immunological diseases, among others. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders. This pipeline, which is being advanced both internally and through PureTech's Founded Entities, is comprised of 24 products and product candidates, including two that have received U.S. Food and Drug Administration (FDA) clearance and European marketing authorization. All of the underlying programs and platforms that resulted in this pipeline of product candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on the Company's unique insights into the biology of the brain, immune and gut, or BIG, systems and the interface between those systems, referred to as the BIG Axis.

For more information, visit [www.puretechhealth.com](http://www.puretechhealth.com) or connect with us on Twitter @puretechh.

### Forward Looking Statement

This press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments, and strategies. The forward looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

### Contact:

#### Investors

Allison Mead Talbot  
+1 617 651 3156  
[amt@puretechhealth.com](mailto:amt@puretechhealth.com)

#### EU media

Ben Atwell, Rob Winder  
+44 (0) 20 3727 1000  
[ben.atwell@FTIconsulting.com](mailto:ben.atwell@FTIconsulting.com)

#### U.S. media

Stephanie Simon  
+1 617 581 9333  
[stephanie@tenbridgecommunications.com](mailto:stephanie@tenbridgecommunications.com)

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rs@lseg.com](mailto:rs@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAGPGUWGUPPPW